Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veru Inc.

0.5698
-0.0116-2.00%
Post-market: 0.57990.0101+1.77%19:52 EDT
Volume:1.85M
Turnover:1.03M
Market Cap:83.41M
PE:-2.17
High:0.5800
Open:0.5614
Low:0.5300
Close:0.5814
Loading ...

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

Compass Therapeutics And 2 More Compelling Penny Stocks

Simply Wall St.
·
02 Apr

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

GlobeNewswire
·
31 Mar

Veru Inc. Shareholders Approve Equity Plan Amendment

TIPRANKS
·
15 Mar

B. Riley Cuts Price Target on Veru to $2 From $5, Keeps Buy Rating

MT Newswires Live
·
07 Mar

Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround

Zacks
·
06 Mar

FOCUS-Next generation weight loss drugs aim to save muscle

Reuters
·
19 Feb

Oppenheimer Adjusts Price Target on Veru to $4 From $5, Keeps Outperform Rating

MT Newswires Live
·
14 Feb

Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...

GuruFocus.com
·
14 Feb

Veru Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Veru Q1 Adj EPS $(0.07) Beats $(0.08) Estimate

Benzinga
·
13 Feb

Veru Inc - Q1 Net Loss From Cont Ops $0.01 per Share

THOMSON REUTERS
·
13 Feb

Veru Q1 2025 GAAP EPS $(0.06) Beats $(0.07) Estimate, Cash, Cash Equivalents, And Restricted Cash Were $26.6M

Benzinga
·
13 Feb

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

GlobeNewswire
·
13 Feb

Veru Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
11 Feb

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

GlobeNewswire
·
06 Feb

Veru Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
04 Feb

Largest borrow rate increases among liquid names

TIPRANKS
·
30 Jan

Veru Inc.’s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm’s Weight Management Potential

TIPRANKS
·
28 Jan